Teva Pharmaceuticals and mAbxience recently announced a strategic licensing agreement for a biosimiliar candidate that is in development for treating multiple oncology indications. The licensing agreement covers multiple global markets, including Europe and the U.S., expanding mAbxience’s global expansion strategy. The new partnership also supports Teva’s “Pivot to Growth” strategy that will expand its biosimiliar…